Published in Cancer Weekly, July 9th, 2002
Mark G. Kris, MD, reported that tumors shrank by half in more than 10% of patients and stabilized in another third following treatment with gefitinib (also known as Iressa or ZD1839). The new drug also reduced symptoms such as shortness of breath, poor appetite, cough, and weight loss in 36% of patients.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.